Trial Profile

EvasayilTM : A Placebo-controlled Trial to Evaluate the Efficacy and Safety of Spesolimab in the Treatment of Patients With Netherton Syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 18 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Spesolimab (Primary) ; Spesolimab (Primary)
Indications Netherton Syndrome
Focus Therapeutic Use
Acronyms EvasayilTM
Sponsors Boehringer Ingelheim

Most Recent Events

12 Jun 2025 Planned End Date changed from 3 Jan 2028 to 24 Jul 2025.
15 Oct 2024 Status changed from recruiting to active, no longer recruiting.
18 Mar 2024 Planned End Date changed from 28 Sep 2026 to 3 Jan 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com